for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Akari Therapeutics PLC (ADR)

AKTX.OQ

Latest Trade

1.82USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

1.56

 - 

9.19

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
1.82
Open
--
Volume
--
3M AVG Volume
23.77
Today's High
--
Today's Low
--
52 Week High
9.19
52 Week Low
1.56
Shares Out (MIL)
1,650.69
Market Cap (MIL)
37.14
Forward P/E
-3.75
Dividend (Yield %)
--

Latest Developments

More

Akari Therapeutics Announces Positive Phase II Clinical Data In Orphan Blistering Skin Disease Bullous Pemphigoid

Akari Therapeutics Reports Qtrly Loss Per Share $0.00

Akari Therapeutics Receives FDA's "Fast Track" Status For Nomacopan

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Akari Therapeutics PLC (ADR)

Akari Therapeutics, Plc, formerly Celsus Therapeutics Plc, is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases caused by dysregulation of complement component 5 (C5), including paroxysmal nocturnal hemoglobinuria, Guillain Barre syndrome and atypical Hemolytic Uremic Syndrome. Its lead drug, Coversin, a complement inhibitor, acts on complement C5, preventing release of C5a and formation of C5b-9. Coversin is a recombinant small protein derived from a protein discovered in the saliva of the Ornithodoros moubata tick, where it modulates the host immune system to allow the parasite to feed without alerting the host to its presence or provoking an immune response. It is conducting Phase Ib clinical trial of Coversin. It focuses on rare and orphan diseases, including disease states spanning hematology, nephrology, transplantation, neurology and ophthalmology.

Industry

Biotechnology & Drugs

Contact Info

75/76 Wimpole Street

+44.20.80040261

http://akaritx.com/

Executive Leadership

Ray Prudo

Chairman of the Board

David Horn Solomon

Chief Executive Officer

Dov Elefant

Chief Financial Officer

Clive Richardson

Chief Operating Officer, Director

Nigel A.S. Hernandez

Vice President - Worldwide Regulatory Affairs

Key Stats

1.50 mean rating - 2 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-2.000

2017

-3.000

2018

-1.080

2019(E)

-0.485
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
-368.75
Return on Equity (TTM)
-123.65

Latest News

Latest News

BRIEF-David Horn Solomon Resigns As CEO Of Akari Therapeutics

* AKARI THERAPEUTICS SAYS ON MAY 8, DAVID HORN SOLOMON, RESIGNED AS CEO AND AS A MEMBER OF BOARD EFFECTIVE IMMEDIATELY - SEC FILING

BRIEF-Akari Therapeutics Qtrly Loss Per Common Share $0.01

* AKARI THERAPEUTICS ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND HIGHLIGHTS RECENT CLINICAL PROGRESS

BRIEF-Akari Therapeutics Says Mid-stage Trial Of Coversin In Patients With Rare Blood Disease PNH Successful

* AKARI THERAPEUTICS ANNOUNCES PHASE II COBALT TRIAL OF COVERSIN™ IN PATIENTS WITH PNH MET THE PRIMARY ENDPOINT

BRIEF-Akari Therapeutics proposes public offering of ADS

* Akari Therapeutics announces proposed public offering of American Depositary Shares Source text for Eikon: Further company coverage:

BRIEF-Akari Therapeutics announces further clinical progress

* Akari Therapeutics - 3 additional patients have been enrolled in ongoing Phase II Cobalt clinical trial of Coversin in patients with PNH

BRIEF-Akari ‍plans to advance its lead drug, Coversin towards Phase III clinical studies in paroxysmal nocturnal hemoglobinuria in Q1 2018​

* plans to advance its lead drug, Coversin towards Phase III clinical studies in paroxysmal nocturnal hemoglobinuria in Q1 2018

BRIEF-Akari Therapeutics appoints David Horn Solomon as CEO

* Akari Therapeutics announces appointment of David Horn Solomon as CEO

BRIEF-Akari Therapeutics PLC files for mixed shelf of up to $100 mln

* Akari Therapeutics PLC files for mixed shelf of up to $100 million – SEC filing Source text: (http://bit.ly/2vLqRqG) Further company coverage:

BRIEF-Akari Therapeutics demonstrates positive response with coversin in ongoing phase 2 PNH trial

* Akari Therapeutics demonstrates positive response with coversin in ongoing phase 2 PNH trial and in additional clinical targets

BRIEF-Akari Therapeutics appoints new members to board

* Akari Therapeutics appoints new members to its board of directors

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up